

Marwan Fakih

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5532354/publications.pdf>

Version: 2024-02-01

214
papers

14,509
citations

36303

51
h-index

22832

112
g-index

217
all docs

217
docs citations

217
times ranked

17396
citing authors

#	ARTICLE	IF	CITATIONS
1	A Phase 2 Trial Combining Pembrolizumab and Palliative Radiation Therapy in Gastroesophageal Cancer to Augment Abscopal Immune Responses. <i>Advances in Radiation Oncology</i> , 2022, 7, 100807.	1.2	4
2	Mucinous Histology Is Associated with Resistance to Anti-EGFR Therapy in Patients with Left-Sided <i>RAS/BRAF</i> Wild-Type Metastatic Colorectal Cancer. <i>Oncologist</i> , 2022, 27, 104-109.	3.7	6
3	Exploratory biomarker analyses of the single-arm, phase 2 study of regorafenib plus nivolumab in patients (pts) with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 89-89.	1.6	1
4	Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 446-454.	8.1	36
5	Safety and efficacy of pressurized intraperitoneal aerosolized chemotherapy in appendiceal and colorectal cancer patients with peritoneal carcinomatosis: A first-in-US phase I study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 125-125.	1.6	0
6	Phase 2 open-label study of pembrolizumab plus lenvatinib and belzutifan in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS669-TPS669.	1.6	0
7	A single-center comparative surveillance strategies of ctDNA (Signatera), imaging, and CEA in the surveillance of resected colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 200-200.	1.6	2
8	Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers. , 2022, 10, e004001.		45
9	Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With <i>NTRK</i> Fusion-Positive Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 1302-1312.	7.0	74
10	Real-World Study of Characteristics and Treatment Outcomes Among Patients with <i>KRAS</i> p.G12C-Mutated or Other <i>KRAS</i> Mutated Metastatic Colorectal Cancer. <i>Oncologist</i> , 2022, 27, 663-674.	3.7	21
11	Evaluation of Comparative Surveillance Strategies of Circulating Tumor DNA, Imaging, and Carcinoembryonic Antigen Levels in Patients With Resected Colorectal Cancer. <i>JAMA Network Open</i> , 2022, 5, e221093.	5.9	21
12	Rechallenge With BRAF and anti-EGFR Inhibitors in Patients With Metastatic Colorectal Cancer Harboring BRAF Mutation Who Progressed on Cetuximab and Encorafenib With or Without Binimetinib: A Case Series. <i>Clinical Colorectal Cancer</i> , 2022, 21, 267-271.	2.3	5
13	Promoting antibody-dependent cellular phagocytosis for effective macrophage-based cancer immunotherapy. <i>Science Advances</i> , 2022, 8, eabl9171.	10.3	30
14	A Phase I Clinical Trial of Trametinib in Combination with TAS-102 in Patients with Chemotherapy-Resistant RAS-Mutated (PIK3CA/PTEN-Wild Type) Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2022, 21, 252-258.	2.3	3
15	Multicenter dose-escalation Phase I trial of mitomycin C pressurized intraperitoneal aerosolized chemotherapy in combination with systemic chemotherapy for appendiceal and colorectal peritoneal metastases: rationale and design. <i>Pleura and Peritoneum</i> , 2022, 7, 169-177.	1.2	2
16	Phase 2 open-label study of pembrolizumab plus lenvatinib and belzutifan in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS4173-TPS4173.	1.6	0
17	Hybrid-control arm construction using historical trial data for an early-phase, randomized controlled trial in metastatic colorectal cancer. <i>Communications Medicine</i> , 2022, 2, .	4.2	5
18	Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 study. <i>European Journal of Cancer</i> , 2022, 171, 259-268.	2.8	19

#	ARTICLE	IF	CITATIONS
19	Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2022, 172, 171-181.	2.8	14
20	Wild-type <i>APC</i> Is Associated with Poor Survival in Metastatic Microsatellite Stable Colorectal Cancer. <i>Oncologist</i> , 2021, 26, 208-214.	3.7	19
21	Chemotherapy-induced early transient increase and surge of CA 19-9 level in patients with pancreatic Adenocarcinoma. <i>Cancer Treatment and Research Communications</i> , 2021, 28, 100397.	1.7	1
22	Rationale and Design of a Telehealth Self-Management, Shared Care Intervention for Post-treatment Survivors of Lung and Colorectal Cancer. <i>Journal of Cancer Education</i> , 2021, 36, 414-420.	1.3	6
23	<i>RAS</i> Amplification as a Negative Predictor of Benefit from Anti-EGFR-Containing Therapy Regimens in Metastatic Colorectal Cancer. <i>Oncologist</i> , 2021, 26, 469-475.	3.7	7
24	Targeting KRAS in Colorectal Cancer. <i>Current Oncology Reports</i> , 2021, 23, 28.	4.0	24
25	Co-stimulatory and co-inhibitory immune markers in solid tumors with MET alterations. <i>Future Science OA</i> , 2021, 7, FSO662.	1.9	1
26	Sequencing Treatments in Hepatocellular Carcinoma: Will Value Frameworks Provide a Solution?. <i>JCO Oncology Practice</i> , 2021, 17, 164-166.	2.9	3
27	MAP2K1 Mutations in Advanced Colorectal Cancer Predict Poor Response to Anti-EGFR Therapy and to Vertical Targeting of MAPK Pathway. <i>Clinical Colorectal Cancer</i> , 2021, 20, 72-78.	2.3	10
28	Building External Control Arms From Patient-Level Electronic Health Record Data to Replicate the Randomized IMblaze370 Control Arm in Metastatic Colorectal Cancer. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 450-458.	2.1	14
29	Targeting MSS colorectal cancer with immunotherapy: are we turning the corner?. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1347-1357.	3.1	14
30	Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 779-789.	10.7	234
31	Evaluation of Somatic Mutations in Solid Metastatic Pan-Cancer Patients. <i>Cancers</i> , 2021, 13, 2776.	3.7	9
32	Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design. <i>Future Oncology</i> , 2021, 17, 1977-1985.	2.4	24
33	Recall of Genomic Testing Results Among Patients with Cancer. <i>Oncologist</i> , 2021, 26, e2302-e2305.	3.7	8
34	Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors. , 2021, 9, e003370.		10
35	Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases. <i>JAMA Network Open</i> , 2021, 4, e2118416.	5.9	62
36	Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines. <i>Annals of Oncology</i> , 2021, 32, 959-967.	1.2	102

#	ARTICLE	IF	CITATIONS
37	Geriatric Assessmentâ€“Driven Intervention (GAIN) on Chemotherapy-Related Toxic Effects in Older Adults With Cancer. JAMA Oncology, 2021, 7, e214158.	7.1	213
38	Potent antitumor effects of cell-penetrating peptides targeting STAT3 axis. JCI Insight, 2021, 6, .	5.0	11
39	Response to PD-1 and PD-L1 based immunotherapy in MSS advanced colorectal cancer is impacted by metastatic disease sites.. Journal of Clinical Oncology, 2021, 39, 72-72.	1.6	5
40	Therapeutic targeting of SLC6A8 creatine transporter suppresses colon cancer progression and modulates human creatine levels. Science Advances, 2021, 7, eabi7511.	10.3	23
41	Response to Trastuzumab and Lapatinib in a Metastatic Colorectal Cancer Harboring HER2 Amplification and HER2 S310F Mutation. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 670-674.	4.9	4
42	Locally advanced anal small cell carcinoma with durable complete response to chemoradiation followed by consolidation chemotherapy: case report and literature review. Journal of Gastrointestinal Oncology, 2021, 12, 3148-3154.	1.4	2
43	The Association of Tumor Laterality and Survival After Cytoreduction for Colorectal Carcinomatosis. Journal of Surgical Research, 2020, 248, 20-27.	1.6	11
44	Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1â€“2 trials. Lancet Oncology, The, 2020, 21, 271-282.	10.7	1,034
45	A Pilot Feasibility Study of Yttrium-90 Liver Radioembolization Followed by Durvalumab and Tremelimumab in Patients with Microsatellite Stable Colorectal Cancer Liver Metastases. Oncologist, 2020, 25, 382-e776.	3.7	23
46	Management Considerations for the Surgical Treatment of Colorectal Cancer During the Global Covid-19 Pandemic. Annals of Surgery, 2020, 272, e98-e105.	4.2	37
47	A novel mesenchymalâ€“associated transcriptomic signature for riskâ€“stratification and therapeutic response prediction in colorectal cancer. International Journal of Cancer, 2020, 147, 3250-3261.	5.1	6
48	SUMOylation of E2F1 Regulates Expression of EZH2. Cancer Research, 2020, 80, 4212-4223.	0.9	12
49	KRAS^{G12C} Inhibition with Sotorasib in Advanced Solid Tumors. New England Journal of Medicine, 2020, 383, 1207-1217.	27.0	1,049
50	Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncology, The, 2020, 21, 1353-1365.	10.7	1,363
51	Regorafenib and Nivolumab or Pembrolizumab Combination and Circulating Tumor DNA Response Assessment in Refractory Microsatellite Stable Colorectal Cancer. Oncologist, 2020, 25, e1188-e1194.	3.7	61
52	Integrating Academic and Community Practices in the Management of Colorectal Cancer: The City of Hope Model. Journal of Clinical Medicine, 2020, 9, 1687.	2.4	5
53	The Role of Palliative Surgery for Malignant Bowel Obstruction and Perforation in Advanced Microsatellite Instability-High Colorectal Carcinoma in the Era of Immunotherapy: Case Report. Frontiers in Oncology, 2020, 10, 581.	2.8	1
54	Safety and Effectiveness of Aflibercept + Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) for the Treatment of Patients with Metastatic Colorectal Cancer (mCRC) in Current Clinical Practice: OZONE Study. Cancers, 2020, 12, 657.	3.7	14

#	ARTICLE	IF	CITATIONS
55	Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next-Generation Sequencing in Detecting Actionable Driver Mutations in Anti-EGFR Naïve Metastatic Colorectal Cancer. <i>Oncologist</i> , 2020, 25, 235-243.	3.7	36
56	Engaging Patients in Precision Oncology: Development and Usability of a Web-Based Patient-Facing Genomic Sequencing Report. <i>JCO Precision Oncology</i> , 2020, 4, 307-318.	3.0	10
57	Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study. <i>Clinical Cancer Research</i> , 2020, 26, 2124-2130.	7.0	132
58	Geriatric assessment-driven intervention (GAIN) on chemotherapy toxicity in older adults with cancer: A randomized controlled trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 12010-12010.	1.6	75
59	Efficacy and safety of entrectinib in patients (pts) with <i>NTRK</i> -fusion positive (<i>NTRK</i> -fp) solid tumors: An updated integrated analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3605-3605.	1.6	33
60	A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4000-4000.	1.6	48
61	CodeBreak 100: Activity of AMG 510, a novel small molecule inhibitor of KRAS ^{G12C} , in patients with advanced colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4018-4018.	1.6	22
62	Pembrolizumab for previously treated advanced anal squamous cell carcinoma: Pooled results from the KEYNOTE-028 and KEYNOTE-158 studies.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4020-4020.	1.6	22
63	Trial in progress: A phase Ib study of AMG 510, a specific and irreversible KRASG12C inhibitor, in combination with other anticancer therapies in patients with advanced solid tumors harboring KRAS p.G12C mutation (CodeBreak 101).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS3661-TPS3661.	1.6	8
64	Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1-1.	1.6	19
65	A phase II study of axalimogene filolisbac for patients with previously treated, unresectable, persistent/recurrent loco-regional or metastatic anal cancer. <i>Oncotarget</i> , 2020, 11, 1334-1343.	1.8	18
66	Neoadjuvant Immunotherapy-Based Systemic Treatment in MMR-Deficient or MSI-High Rectal Cancer: Case Series. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 798-804.	4.9	33
67	Phase I monotherapy dose escalation of RGX-202, a first-in-class oral inhibitor of the SLC6a8/CKB pathway, in patients with advanced gastrointestinal (GI) solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3504-3504.	1.6	3
68	Clinical Response to T-DM1 in HER2-Amplified, KRAS-Mutated Metastatic Colorectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 116-119.	4.9	4
69	Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel. <i>Clinical Cancer Research</i> , 2019, 25, 7035-7045.	7.0	152
70	The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. <i>Nature</i> , 2019, 575, 217-223.	27.8	1,375
71	Efficacy of PD-1 Blockade in Refractory Microsatellite-Stable Colorectal Cancer With High Tumor Mutation Burden. <i>Clinical Colorectal Cancer</i> , 2019, 18, 307-309.	2.3	6
72	Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. <i>Annals of Oncology</i> , 2019, 30, 1096-1103.	1.2	456

#	ARTICLE	IF	CITATIONS
73	Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2019, 20, 849-861.	10.7	368
74	Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. <i>Lancet Oncology</i> , The, 2019, 20, 518-530.	10.7	362
75	Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With <i>BRAF</i> V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1460-1469.	1.6	188
76	Systemic treatment for metastatic colorectal cancer in the era of precision medicine. <i>Journal of Surgical Oncology</i> , 2019, 119, 564-582.	1.7	55
77	A Pilot Study of Vinorelbine Safety and Pharmacokinetics in Patients with Varying Degrees of Liver Dysfunction. <i>Oncologist</i> , 2019, 24, 1137-1145.	3.7	2
78	A case of class 3 MEK1 mutated metastatic colorectal cancer with a non-durable tumor marker response to MEK and ERK inhibitors. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 1140-1143.	1.4	7
79	Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy. <i>Oncologist</i> , 2019, 24, 1340-1347.	3.7	73
80	Validation of <i>HER2</i> Amplification as a Predictive Biomarker for Anti-Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-13.	3.0	46
81	Allosteric Inhibition of Ubiquitin-like Modifications by a Class of Inhibitor of SUMO-Activating Enzyme. <i>Cell Chemical Biology</i> , 2019, 26, 278-288.e6.	5.2	36
82	A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105. <i>Cancer Discovery</i> , 2019, 9, 384-395.	9.4	88
83	Immune overdrive signature in colorectal tumor subset predicts poor clinical outcome. <i>Journal of Clinical Investigation</i> , 2019, 129, 4464-4476.	8.2	64
84	Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule <i>KRAS</i> ^{G12C} inhibitor, in advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3003-3003.	1.6	145
85	Updated results of the BEACON CRC safety lead-in: Encorafenib (ENCO) + binimetinib (BINI) + cetuximab (CETUX) for BRAFV600E-mutant metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 688-688.	1.6	14
86	Impact of Surgical Resection on Survival Outcomes After Chemoradiotherapy in Anal Adenocarcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1203-1210.	4.9	14
87	PD-1 Blockade in a Liver Transplant Recipient With Microsatellite Unstable Metastatic Colorectal Cancer and Hepatic Impairment. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1026-1030.	4.9	12
88	Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in <i>ERBB2</i> and <i>ERBB3</i> . <i>Cancer</i> , 2018, 124, 1358-1373.	4.1	151
89	Trastuzumab Plus Pertuzumab Resistance Does Not Preclude Response to Lapatinib Plus Trastuzumab in HER2-Amplified Colorectal Cancer. <i>Oncologist</i> , 2018, 23, 474-477.	3.7	11
90	Rationale, development, and design of the Altering Intake , Managing Symptoms (AIMS) dietary intervention for bowel dysfunction in rectal cancer survivors. <i>Contemporary Clinical Trials</i> , 2018, 68, 61-66.	1.8	12

#	ARTICLE	IF	CITATIONS
91	Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition. Journal of Gastrointestinal Oncology, 2018, 9, 610-617.	1.4	192
92	Immune profiling of microsatellite instability-high and polymerase Îµ (POLE)-mutated metastatic colorectal tumors identifies predictors of response to anti-PD-1 therapy. Journal of Gastrointestinal Oncology, 2018, 9, 404-415.	1.4	49
93	Complete response to pembrolizumab in a patient with metastatic colon cancer with microsatellite instability and a history of Guillain-Barre syndrome. Journal of Gastrointestinal Oncology, 2018, 10, 161-165.	1.4	12
94	Value-based genomics. Oncotarget, 2018, 9, 15792-15815.	1.8	46
95	BEACON CRC study safety lead-in (SLI) in patients with <i>BRAF</i> ^{V600E} metastatic colorectal cancer (mCRC): Efficacy and tumor markers.. Journal of Clinical Oncology, 2018, 36, 627-627.	1.6	32
96	Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a <i>POLE</i> Mutation. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 142-147.	4.9	182
97	Empowering survivors after colorectal and lung cancer treatment: Pilot study of a Self-Management Survivorship Care Planning intervention. European Journal of Oncology Nursing, 2017, 29, 125-134.	2.1	39
98	Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-Fluorouracil and capecitabine toxicity. Cancer, 2017, 123, 345-356.	4.1	91
99	Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience. Oncotarget, 2017, 8, 42198-42213.	1.8	49
100	A single institute retrospective trial of concurrent chemotherapy with SIR-Spheres® versus SIR-Spheres® alone in chemotherapy-resistant colorectal cancer liver metastases. Journal of Gastrointestinal Oncology, 2017, 8, 608-613.	1.4	3
101	Pilot trial of CRLX101 in patients with advanced, chemotherapy-refractory gastroesophageal cancer. Journal of Gastrointestinal Oncology, 2017, 8, 962-969.	1.4	23
102	Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: expert consensus. Journal of Gastrointestinal Oncology, 2017, 8, 1079-1099.	1.4	34
103	Chemotherapy in patients with hepatobiliary cancers and abnormal hepatic function. Journal of Gastrointestinal Oncology, 2017, 8, 314-323.	1.4	5
104	The International Duration Evaluation of Adjuvant Chemotherapy study: implications for clinical practice. Journal of Gastrointestinal Oncology, 2017, 8, 603-607.	1.4	2
105	Biological Therapy in Colorectal Cancer in the Era of Sidedness. Oncology Times, 2017, 39, 1,9-11.	0.1	3
106	Pertuzumab + trastuzumab for HER2-amplified/overexpressed metastatic colorectal cancer (mCRC): Interim data from MyPathway.. Journal of Clinical Oncology, 2017, 35, 676-676.	1.6	30
107	A phase I clinical trial of binimetinib in combination with FOLFOX in patients with advanced metastatic colorectal cancer who failed prior standard therapy. Oncotarget, 2017, 8, 79750-79760.	1.8	12
108	MEK162 Enhances Antitumor Activity of 5-Fluorouracil and Trifluridine in KRAS-mutated Human Colorectal Cancer Cell Lines. Anticancer Research, 2017, 37, 2831-2838.	1.1	11

#	ARTICLE	IF	CITATIONS
109	Impressive response to dual BRAF and MEK inhibition in patients with BRAF mutant intrahepatic cholangiocarcinoma—2 case reports and a brief review. <i>Journal of Gastrointestinal Oncology</i> , 2016, 6, E98-E102.	1.4	46
110	RAS and BRAF in metastatic colorectal cancer management. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 687-704.	1.4	56
111	Reliability, Validity, and Feasibility of a Computer-Based Geriatric Assessment for Older Adults With Cancer. <i>Journal of Oncology Practice</i> , 2016, 12, e1025-e1034.	2.5	83
112	Pilot study of an interdisciplinary supportive care planning intervention in pancreatic cancer. <i>Supportive Care in Cancer</i> , 2016, 24, 3417-3424.	2.2	13
113	Economic Analysis of Panitumumab Compared With Cetuximab in Patients With Wild-type KRAS Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy. <i>Clinical Therapeutics</i> , 2016, 38, 1376-1391.	2.5	11
114	Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer. <i>Oncologist</i> , 2016, 21, 1306-1314.	3.7	36
115	Role of SUMO activating enzyme in cancer stem cell maintenance and self-renewal. <i>Nature Communications</i> , 2016, 7, 12326.	12.8	78
116	Effect of increasing radiation dose on pathologic complete response in rectal cancer patients treated with neoadjuvant chemoradiation therapy. <i>Acta Oncologica</i> , 2016, 55, 1392-1399.	1.8	43
117	Epidermal Growth Factor Receptor Signaling to the Mitogen Activated Protein Kinase Pathway Bypasses Ras in Pancreatic Cancer Cells. <i>Pancreas</i> , 2016, 45, 286-292.	1.1	12
118	The state of regional therapy in the management of metastatic colorectal cancer to the liver. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 229-245.	2.4	5
119	HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3517-3517.	1.6	59
120	Impact of RAS and BRAF mutations on carcinoembryonic antigen production and pattern of colorectal metastases. <i>World Journal of Gastrointestinal Oncology</i> , 2016, 8, 128.	2.0	13
121	An update on anti-EGF receptor therapy and the move towards targeted therapy and precision medicine. <i>Colorectal Cancer</i> , 2015, 4, 9-11.	0.8	0
122	Biologic Therapies in Colorectal Cancer: Indications and Contraindications. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e197-e206.	3.8	7
123	Metastatic Colorectal Cancer: Current State and Future Directions. <i>Journal of Clinical Oncology</i> , 2015, 33, 1809-1824.	1.6	418
124	Cost-minimization analysis of panitumumab compared with cetuximab for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. <i>Journal of Medical Economics</i> , 2015, 18, 619-628.	2.1	9
125	Vitamin D and colorectal cancer: is it time for D3 supplementation in patients with metastatic disease?. <i>Colorectal Cancer</i> , 2015, 4, 59-62.	0.8	1
126	Accuracy of computed tomography in nodal staging of colon cancer patients. <i>World Journal of Gastrointestinal Surgery</i> , 2015, 7, 116.	1.5	18

#	ARTICLE	IF	CITATIONS
127	p53MVA Therapy in Patients with Refractory Gastrointestinal Malignancies Elevates p53-Specific CD8+ T-cell Responses. <i>Clinical Cancer Research</i> , 2014, 20, 4459-4470.	7.0	32
128	SIR-Spheres [®] radioembolization in the management of metastatic colorectal cancer: a medical oncology perspective. <i>Colorectal Cancer</i> , 2014, 3, 331-343.	0.8	0
129	A Case of Fibrolamellar Cancer With a Palliative Response and Minor Radiographic Regression With Erlotinib and Bevacizumab Combination Therapy. <i>American Journal of Therapeutics</i> , 2014, 21, e207-e210.	0.9	10
130	The emerging role of neoadjuvant chemotherapy for rectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2014, 5, 362-73.	1.4	29
131	Serum Vitamin D Metabolites in Colorectal Cancer Patients Receiving Cholecalciferol Supplementation: Correlation with Polymorphisms in the Vitamin D Genes. <i>Hormones and Cancer</i> , 2013, 4, 242-250.	4.9	34
132	Targeting mechanisms of resistance to anti-EGF receptor therapy in KRAS wild-type colorectal cancer: the path to more personalized medicine. <i>Future Oncology</i> , 2013, 9, 551-560.	2.4	9
133	TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer. <i>Cancer</i> , 2013, 119, 4290-4298.	4.1	53
134	The evolving role of VEGF-targeted therapies in the treatment of metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 427-438.	2.4	13
135	Targeting angiogenesis beyond first-line bevacizumab progression: ziv-aflibercept or more bevacizumab?. <i>Colorectal Cancer</i> , 2013, 2, 9-12.	0.8	1
136	A contemporary analysis of morbidity and outcomes in cytoreduction/hyperthermic intraperitoneal chemoperfusion. <i>Cancer Medicine</i> , 2013, 2, 334-342.	2.8	50
137	Gastric Cancer, Version 2.2013. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 531-546.	4.9	422
138	Metastatic Colon Cancer, Version 3.2013. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 141-152.	4.9	130
139	Localized Colon Cancer, Version 3.2013. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 519-528.	4.9	81
140	TP53 and Let-7a micro-RNA Regulate K-Ras Activity in HCT116 Colorectal Cancer Cells. <i>PLoS ONE</i> , 2013, 8, e70604.	2.5	22
141	Impact of medical and surgical intervention on survival in patients with cholangiocarcinoma. <i>World Journal of Gastrointestinal Surgery</i> , 2013, 5, 178.	1.5	10
142	Targeted therapies in colorectal cancer: the dos, don'ts, and future directions. <i>Journal of Gastrointestinal Oncology</i> , 2013, 4, 239-44.	1.4	0
143	Intensive Radiographic and Biomarker Surveillance in Stage II and III Colorectal Cancer. <i>Oncology</i> , 2012, 82, 41-47.	1.9	17
144	Anal Carcinoma, Version 2.2012. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 449-454.	4.9	67

#	ARTICLE	IF	CITATIONS
145	Interview: Recent advances in first-line treatment of metastatic colorectal cancer. Colorectal Cancer, 2012, 1, 111-114.	0.8	0
146	Intensive screening for resected stage II and III colorectal cancer. Colorectal Cancer, 2012, 1, 71-81.	0.8	0
147	Rectal Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 1528-1564.	4.9	138
148	Phase II Study of Irinotecan and Cetuximab Given Every 2 Weeks as Second-Line Therapy for Advanced Colorectal Cancer. Clinical Colorectal Cancer, 2012, 11, 53-59.	2.3	13
149	A randomized phase II study of two doses of vorinostat in combination with 5-FU/LV in patients with refractory colorectal cancer. Cancer Chemotherapy and Pharmacology, 2012, 69, 743-751.	2.3	40
150	Methyl Selenocysteine: Single-Dose Pharmacokinetics in Men. Cancer Prevention Research, 2011, 4, 1938-1944.	1.5	26
151	Serological immune responses to influenza vaccine in patients with colorectal cancer. Cancer Chemotherapy and Pharmacology, 2011, 67, 111-115.	2.3	16
152	Effect of 25-hydroxyvitamin D status on serological response to influenza vaccine in prostate cancer patients. Prostate, 2011, 71, 368-372.	2.3	50
153	Making sense of anti-EGFR plus oxaliplatin-based therapy in the first-line treatment of metastatic colorectal cancer. Future Oncology, 2011, 7, 223-226.	2.4	0
154	First-line cisplatin plus etoposide in high-grade metastatic neuroendocrine tumors of colon and rectum (MCRC NET): review of 8 cases. Anticancer Research, 2011, 31, 975-8.	1.1	43
155	Single-agent paclitaxel in advanced anal cancer after failure of cisplatin and 5-fluorouracil chemotherapy. Anticancer Research, 2011, 31, 4637-40.	1.1	26
156	Anal Carcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 106-120.	4.9	64
157	Quantitative methodology using CT for predicting survival in patients with metastatic colorectal carcinoma: a pilot study. Clinical Imaging, 2010, 34, 196-202.	1.5	2
158	Analysis of Clinical and Dosimetric Factors Associated With Change in Renal Function in Patients With Gastrointestinal Malignancies After Chemoradiation to the Abdomen. International Journal of Radiation Oncology Biology Physics, 2010, 76, 1193-1198.	0.8	14
159	Renal Atrophy Secondary to Chemoradiotherapy of Abdominal Malignancies. International Journal of Radiation Oncology Biology Physics, 2010, 78, 539-546.	0.8	16
160	Randomized, Phase II Study of the Insulin-Like Growth Factor-1 Receptor Inhibitor IMC-A12, With or Without Cetuximab, in Patients With Cetuximab- or Panitumumab-Refractory Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2010, 28, 4240-4246.	1.6	129
161	A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Two Schedules of Vorinostat in Combination with 5-Fluorouracil and Leucovorin in Patients with Refractory Solid Tumors. Clinical Cancer Research, 2010, 16, 3786-3794.	7.0	40
162	KRAS Mutation Screening in Colorectal Cancer: From Paper to Practice. Clinical Colorectal Cancer, 2010, 9, 22-30.	2.3	22

#	ARTICLE	IF	CITATIONS
163	Efficacy of the Monoclonal Antibody EGFR Inhibitors for the Treatment of Metastatic Colorectal Cancer. <i>Current Oncology</i> , 2010, 17, 3-17.	2.2	63
164	KRAS status and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFOX chemotherapy. <i>Journal of Gastrointestinal Oncology</i> , 2010, 1, 90-6.	1.4	8
165	Positron emission tomography as predictor of rectal cancer response during or following neoadjuvant chemoradiation. <i>World Journal of Gastrointestinal Oncology</i> , 2010, 2, 213.	2.0	7
166	Predictive or non-predictive, prognostic or non-prognostic: Dilemmas generated through small retrospective studies. <i>Journal of Gastrointestinal Oncology</i> , 2010, 1, 72-3.	1.4	1
167	A Phase I, Pharmacokinetic and Pharmacodynamic Study on Vorinostat in Combination with 5-Fluorouracil, Leucovorin, and Oxaliplatin in Patients with Refractory Colorectal Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 3189-3195.	7.0	61
168	Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301. <i>Journal of Clinical Oncology</i> , 2009, 27, 1800-1805.	1.6	195
169	Chemotherapy is linked to severe vitamin D deficiency in patients with colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2009, 24, 219-224.	2.2	74
170	A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 65, 33-40.	2.3	41
171	Vitamin D deficiency and insufficiency among patients with prostate cancer. <i>BJU International</i> , 2009, 104, 909-914.	2.5	43
172	A phase II study of first-line biweekly capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 71, 242-248.	4.4	15
173	Does Celecoxib Have a Role in the Treatment of Patients with Colorectal Cancer?. <i>Clinical Colorectal Cancer</i> , 2009, 8, 11-14.	2.3	11
174	A Case of 5-Fluorouracil-Induced Acute Psychosis. <i>Clinical Colorectal Cancer</i> , 2009, 8, 166-168.	2.3	7
175	Colon Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, 778-831.	4.9	409
176	A Phase I and pharmacokinetic study of selenomethionine in combination with a fixed dose of irinotecan in solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 499-508.	2.3	31
177	Polyamine catabolism in colorectal cancer cells following treatment with oxaliplatin, 5-fluorouracil and N 1 , N 11 diethylnorspermine. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 517-527.	2.3	29
178	The Role of Targeted Therapy in the Treatment of Advanced Colorectal Cancer. <i>Current Treatment Options in Oncology</i> , 2008, 9, 357-374.	3.0	5
179	Significance of Signet-Ring Cells in Patients with Colorectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2008, 51, 50-55.	1.3	95
180	Qualitative radiology assessment of tumor response: does it measure up?. <i>Clinical Imaging</i> , 2008, 32, 136-140.	1.5	2

#	ARTICLE	IF	CITATIONS
181	Anti-EGFR monoclonal antibodies in metastatic colorectal cancer: time for an individualized approach?. Expert Review of Anticancer Therapy, 2008, 8, 1471-1480.	2.4	12
182	Management of anti-EGFR-targeting monoclonal antibody-induced hypomagnesemia. Oncology, 2008, 22, 74-6.	0.5	31
183	A Phase I Pharmacokinetic and Pharmacodynamic Study of Intravenous Calcitriol in Combination with Oral Gefitinib in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2007, 13, 1216-1223.	7.0	75
184	Anti-EGFR monoclonal antibody-induced hypomagnesaemia. Lancet Oncology, The, 2007, 8, 366-367.	10.7	22
185	Toxicities and Survival Among Octogenarians and Nonagenarians with Colorectal Cancer Treated with Chemotherapy or Concurrent Chemoradiation Therapy. Clinical Colorectal Cancer, 2007, 6, 362-366.	2.3	13
186	Reversible Grade 4 Hyperbilirubinemia in a Patient with UGT1A1 7/7 Genotype Treated with Irinotecan and Cetuximab. Clinical Colorectal Cancer, 2007, 6, 447-449.	2.3	9
187	Increased Frequency of Uridine Diphosphate Glucuronosyltransferase 1A1 7/7 in Patients Experiencing Severe Irinotecan-Induced Toxicities. Clinical Colorectal Cancer, 2007, 6, 583-587.	2.3	7
188	Safety and Efficacy of First-Line Chemotherapy in Unresected Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2007, 6, 710-715.	2.3	8
189	Efficacy of increasing the therapeutic index of irinotecan, plasma and tissue selenium concentrations is methylselenocysteine dose dependent. Biochemical Pharmacology, 2007, 73, 1280-1287.	4.4	25
190	Selenium metabolites in urine of cancer patients receiving l-selenomethionine at high doses. Toxicology and Applied Pharmacology, 2007, 220, 211-215.	2.8	35
191	A Phase II Study of Gemcitabine and Capecitabine in Advanced Cholangiocarcinoma and Carcinoma of the Gallbladder: A Single-Institution Prospective Study. Annals of Surgical Oncology, 2007, 14, 3202-3209.	1.5	68
192	Cetuximab-Induced Hypomagnesemia in Patients with Colorectal Cancer. Clinical Colorectal Cancer, 2006, 6, 152-156.	2.3	101
193	Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers. Cancer Chemotherapy and Pharmacology, 2006, 57, 465-474.	2.3	8
194	Selenium supplementation and colorectal adenomas: An analysis of the nutritional prevention of cancer trial. International Journal of Cancer, 2006, 118, 1777-1781.	5.1	74
195	Bevacizumab-Induced Nasal Septum Perforation. Oncologist, 2006, 11, 85-86.	3.7	50
196	Concurrent oxaliplatin, capecitabine, and radiation therapy in the neoadjuvant therapy of rectal adenocarcinoma: can we get the right dose first?. Annals of Oncology, 2006, 17, 1029-1030.	1.2	0
197	Chemotherapy-Induced Carcinoembryonic Antigen Surge in Patients with Metastatic Colorectal Cancer. Oncology, 2006, 70, 49-53.	1.9	29
198	Irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. Expert Opinion on Pharmacotherapy, 2006, 7, 687-703.	1.8	11

#	ARTICLE	IF	CITATIONS
199	Vitamin D compounds: clinical development as cancer therapy and prevention agents. <i>Anticancer Research</i> , 2006, 26, 2551-6.	1.1	59
200	Prevention of colorectal cancer: an emerging role for high-dose vitamin D supplementation?. <i>Oncology</i> , 2006, 20, 1707-10.	0.5	1
201	Postoperative Computed Tomography Scan Surveillance for Patients With Stage II and III Colorectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2005, 28, 30-35.	1.3	9
202	Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 55, 354-360.	2.3	16
203	Phase I and Pharmacokinetic Study of Weekly Docetaxel, Cisplatin, and Daily Capecitabine in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2005, 11, 5942-5949.	7.0	5
204	Selenium Protects Against Toxicity Induced by Anticancer Drugs and Augments Antitumor Activity: A Highly Selective, New, and Novel Approach for the Treatment of Solid Tumors. <i>Clinical Colorectal Cancer</i> , 2005, 5, 132-135.	2.3	48
205	Phase I and Pharmacologic Study of Intermittently Administered 9-Nitrocamptothecin in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2004, 10, 5058-5064.	7.0	17
206	First-line hepatic infusion of pirarubicin in patients with isolated liver metastases: is it really promising?. <i>Annals of Oncology</i> , 2004, 15, 359.	1.2	0
207	A report of high-dose selenium supplementation: response and toxicities. <i>Journal of Trace Elements in Medicine and Biology</i> , 2004, 18, 69-74.	3.0	175
208	Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 54, 487-496.	2.3	20
209	Anti-tumor activity of calcitriol: pre-clinical and clinical studies. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2004, 89-90, 519-526.	2.5	150
210	Glucocorticoids and treatment of prostate cancer: a preclinical and clinical review. <i>Urology</i> , 2002, 60, 553-561.	1.0	64
211	Intramedullary spinal cord metastasis (ISCM) in renal cell carcinoma: A series of six cases. <i>Annals of Oncology</i> , 2001, 12, 1173-1177.	1.2	66
212	Unusual Tumors Involving the Head and Neck Region. <i>Journal of Clinical Oncology</i> , 2001, 19, 4173-4174.	1.6	10
213	Inhibition of prostate cancer growth by estramustine and colchicine. <i>Prostate</i> , 1995, 26, 310-315.	2.3	26
214	Targeting KRASG12C-Mutated Advanced Colorectal Cancer: Research and Clinical Developments. <i>OncoTargets and Therapy</i> , 0, Volume 15, 747-756.	2.0	14